EMA's veterinary signal page: phenobarbital dog labelling, new MAH templates, VeDDRA list

What happened

On 13 November 2026, EMA updated its veterinary signal management page. The page sets out marketing authorisation holder (MAH) duties, revised templates and the outcome of a closed targeted review of phenobarbital products. That review recommended product information changes for dogs.

Two related documents appeared the same day. The first is the final EU-language translations of the phenobarbital product information text, linked to the targeted signal management procedure. The second is a draft guideline on veterinary good pharmacovigilance practices (VGVP) containing a list of medically important VeDDRA terms.

The phenobarbital review: what is and isn't known

The records confirm that the review is closed, that it covered phenobarbital products and that it recommended product information changes for dogs. The publication of final translations suggests the wording has reached the stage where national implementation can follow. The records do not state what the changes are, which sections of the product information they touch, or what deadline MAHs have to implement them. Teams holding phenobarbital veterinary authorisations should read the annex text directly rather than rely on summaries.

The case also shows how a targeted signal procedure works in practice. A specific safety question about an active substance is examined across products. The result is harmonised product information text that is then translated for every EU language.

Why the templates and the VeDDRA list matter

The page also covers revised MAH templates. The records do not say what changed in them. Even so, template revisions in a signal process usually affect the structure and content of what MAHs submit, so they deserve a gap check against your current procedures.

The draft guideline matters for a different reason. According to the records, it would replace the current appendix to the VGVP signal management module. Comments are open until 31 January 2027, alongside a separate consultation on the module's revision. The two consultations are linked. A list of medically important VeDDRA terms feeds into how adverse event reports are screened and prioritised, so changes to the list could alter which reports get closer attention. The records do not say which terms are on the draft list or how it differs from the current appendix. Those differences are the first thing a PV team should establish.

Who is affected

The most directly affected are MAHs of phenobarbital veterinary medicines, who must act on the dog-related product information changes. All EU veterinary MAHs and their PV staff are affected by the updated duties and templates. They also have a stake in the draft VeDDRA list, because it may reshape signal detection routines and the criteria written into their SOPs.

Contract PV providers and database vendors serving veterinary clients should also watch the consultation. A change to the list of medically important terms could mean reconfiguring case-triage rules and reporting dashboards.

Not every item in the day's news feed is relevant here. The FTC's suit to block Covetrus's $3.5bn acquisition of MWI concerns veterinary distribution and competition, not pharmacovigilance. The records do not link it to the EMA developments.

What to watch

The key date is 31 January 2027, when both VGVP consultations close. Companies with views on the medically important terms or the revised signal management module have a limited window to comment. The records do not say when a final guideline might be adopted, so no timeline should be assumed.

Teams should also watch how national authorities handle the phenobarbital translations once the final texts are available, since the records give no implementation deadline. A reasonable internal approach is to compare the new templates and the draft term list with current signal management SOPs now. Gaps can then be addressed before the guidance is finalised, not after.